Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Published:2020-04 Issue:5 Volume:72 Page:761-768
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Vollenhoven Ronald F.¹^ORCID,Hahn Bevra H.²,Tsokos George C.³^ORCID,Lipsky Peter⁴,Fei Kaiyin⁵,Gordon Robert M.⁵,Gregan Irene⁵,Lo Kim Hung⁵,Chevrier Marc⁵,Rose Shawn⁵

Affiliation:

1. University of Amsterdam Amsterdam The Netherlands

2. University of California Los Angeles

3. Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts

4. AMPEL BioSolutions, LLC Charlottesville Virginia

5. Janssen Research & Development, LLC Spring House Pennsylvania

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41179